Yacoub Magdi H, Klieverik Loes M A, Melina Giovanni, Edwards Sue E R, Sarathchandra Padmini, Bogers Ad J J C, Squarcia Umberto, Sani Guido, van Herwerden Lex A, Takkenberg Johanna J M
Harefield Heart Science Center, NHLI, UK.
J Heart Valve Dis. 2006 Jul;15(4):531-9.
Pulmonary autograft replacement of the aortic valve (the Ross operation) is the operation of choice in infants and children. Although this procedure can offer theoretical advantages at any age, its use in adults remains controversial.
A total of 264 consecutive patients (203 males, 61 females; mean age 35.0 +/- 11.5 years; range: 18-66 years) was studied. These patients underwent the Ross operation at two institutions and were followed up for a total of 1,634 patient-years. The etiology was mainly congenital (52%), degenerative (22%), and rheumatic (8%). Among patients, 21% underwent prior aortic valve replacement.
Thirty-day mortality was 2.3% (n = 6), and four more patients died during follow up (mean follow up 6.2 years; range 0-15.4 years). Cumulative survival at five years was 96.8%, and at 10 years was 95.4%. Eleven patients underwent reoperation on the aortic valve; this was due to progressive dilatation and aortic regurgitation in 10 cases, and to dissection of the arterial wall of the autograft in one case. Overall freedom from pulmonary homograft reoperation was 94.9% at 10 years, and for autograft reoperation was 92.9%. Estimated freedom from autograft reoperation at Harefield was 98.6% at five and 10 years, and at Rotterdam 96.0% at five years and 88.2% at 10 years (p = 0.10, Tyrone-Ware). No risk factors for early and late mortality and reoperation were detected.
In this combined series, the Ross operation in adult patients resulted in excellent survival and acceptable reoperation rates. A prospective randomized trial is proposed to study whether this observation truly reflects the potential advantages of the Ross procedure, or whether it is caused by patient selection.
采用肺动脉自体移植替换主动脉瓣(罗斯手术)是婴幼儿和儿童的首选手术方式。尽管该手术在任何年龄段理论上都具有优势,但其在成人中的应用仍存在争议。
共对264例连续患者(男性203例,女性61例;平均年龄35.0±11.5岁;范围:18 - 66岁)进行了研究。这些患者在两家机构接受了罗斯手术,并进行了总计1634患者年的随访。病因主要为先天性(52%)、退行性(22%)和风湿性(8%)。患者中,21%曾接受过主动脉瓣置换术。
30天死亡率为2.3%(n = 6),随访期间另有4例患者死亡(平均随访6.2年;范围0 - 15.4年)。5年累计生存率为96.8%,10年为95.4%。11例患者接受了主动脉瓣再次手术;其中10例是由于进行性扩张和主动脉反流,1例是由于自体移植物动脉壁夹层。10年时总体免于肺动脉同种异体移植再次手术率为94.9%,自体移植物再次手术率为92.9%。在哈雷菲尔德,5年和10年时自体移植物再次手术预计免于率分别为98.6%,在鹿特丹5年时为96.0%,10年时为88.2%(p = 0.10,泰隆 - 韦尔检验)。未检测到早期和晚期死亡及再次手术的危险因素。
在这个综合系列研究中,成人患者的罗斯手术取得了出色的生存率和可接受的再次手术率。建议进行一项前瞻性随机试验,以研究这一观察结果是真正反映了罗斯手术的潜在优势,还是由患者选择导致的。